CMF Classification

Similar items

• The cell density factor CMF regulates the chemoattractant receptor cAR1 in Dictyostelium

  Scholarly record1996The Journal of Cell BiologyP J Van Haastert, J D Bishop, R H Gomer

  Starving Dictyostelium cells aggregate by chemotaxis to cAMP when a secreted protein called conditioned medium factor (CMF) reaches a threshold concentration. Cells expressing CMF antisense mRNA fail to aggregate and do not transduce signals from the cAMP receptor. Signal transdu

• Validation of CMFs Derived from Cross-Sectional Studies Using Regression Models

  Scholarly record2014Lingtao Wu

  1 Crash modification factors (CMFs) can be used to capture the safety effects of countermeasures 2 and play significant roles in traffic safety management. As an alternative to the before-after 3 study, the regression model method has been widely used for estimating CMFs. Althoug

• adjuvant chemotherapy of early stage breast cancer in community-based cancer treatment fields: cmf compared with anthracycline/taxane-based regimens

  Articlemiddle east journal of cancernarges bayat mokhtari cancer research center, mashhad university of medical sciences, mashhad, iran, roham salek cancer research center, mashhad university of medical sciences, mashhad, iran, fatemeh homaee shandiz cancer research center, mashhad university of medical sciences, mashhad, iran, soodabeh shahidsales cancer research center, mashhad university of medical sciences, mashhad, iran

  introduction: mortality rate of breast cancer has been fallen in recent years. combination of cyclophosphamide, methotrexate, and 5-fluorouracil(cmf), as a pioneer of adjuvant chemotherapy of breast cancer, and later introduced anthracycline/taxane(a/t)-based regimens have both p

• Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.

  Scholarly record2002CancerGiorgio Cocconi, Beatrice Di Blasio, Corrado Boni, Giancarlo Bisagni

  BACKGROUND According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is

• CMF revisited in the 21st century.

  Scholarly record2012Annals of oncology : official journal of the European Society for Medical OncologyE Munzone, G Curigliano, H J Burstein, E P Winer

  Over the last 35 years, classical CMF (combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil) has been a milestone in the adjuvant treatment of women with breast cancer. However, after an early burst of success lasted just over 10 years, classical CMF has

• Adjuvant Chemotherapy of Early Stage Breast Cancer in Community-based Cancer Treatment Fields: CMF Compared with Anthracycline/Taxane-based Regimens

  Article2017Middle East Journal of CancerNarges Bayat Mokhtari, Roham Salek, Fatemeh Homaee Shandiz, Soodabeh Shahidsales

  Introduction: Mortality rate of breast cancer has been fallen in recent years. Combination of cyclophosphamide, methotrexate, and 5-fluorouracil(CMF), as a pioneer of adjuvant chemotherapy of breast cancer, and later introduced anthracycline/taxane(A/T)-based regimens have both p